Table 3.
Differences in demographic and clinical-therapeutic variables between females and males
| Variables | Females (n = 192) | Males (n = 308) | p |
| Age (y) | 64 (57 –72) | 67 (59 –74) | 0.025 |
| Weight (kg) | 63 (57 –72) | 78 (70 –87) | <0.001 |
| Height (cm) | 160 (158 –165) | 173 (170 –179) | <0.001 |
| BMI (kg/cm2) | 24.4 (22.1 –28.0) | 25.9 (23.8 –28.5) | 0.001 |
| Duration of LD therapy (y) | 2 (1 –5) | 2 (0.5 –4) | 0.029 |
| LD test dose (mg/kg) | 1.6 (1.4 –1.9) | 1.3 (1.2 –1.6) | <0.001 |
| Amantadine –n° (%) | 17 (8.9) | 10 (3.6) | 0.007 |
| Other cotherapies | |||
| Antihypertensive –n° (%) | 67 (34.9) | 150 (48.7) | 0.002 |
| Ipothyroidism –n° (%) | 19 (9.9) | 10 (3.3) | 0.002 |
| Antidepressant –n° (%) | 74 (38.5) | 81 (26.3) | 0.004 |
| Coffee consumption –n° (%) | 119 (63.3) | 221 (72.7) | 0.028 |
| Alcohol consumption –n° (%) | 46 (24.6) | 158 (52.3) | <0.001 |
Values are expressed as median (interquartiles). BMI, body mass index; LD, levodopa.